Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century

One hundred million deaths were caused by tobacco in the 20th century, and it is estimated that there will be up to one billion deaths attributed to tobacco use in the 21st century. Chronic obstructive pulmonary disease (COPD) is rapidly becoming a global public health crisis with smoking being reco...

Full description

Bibliographic Details
Main Author: Rafael Laniado-Laborín
Format: Article
Language:English
Published: MDPI AG 2009-01-01
Series:International Journal of Environmental Research and Public Health
Subjects:
Online Access:http://www.mdpi.com/1660-4601/6/1/209/
id doaj-f00e55cc816f4488869ad7a5e10dba1b
record_format Article
spelling doaj-f00e55cc816f4488869ad7a5e10dba1b2020-11-25T00:10:59ZengMDPI AGInternational Journal of Environmental Research and Public Health1660-46012009-01-016120922410.3390/ijerph6010209Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st CenturyRafael Laniado-LaborínOne hundred million deaths were caused by tobacco in the 20th century, and it is estimated that there will be up to one billion deaths attributed to tobacco use in the 21st century. Chronic obstructive pulmonary disease (COPD) is rapidly becoming a global public health crisis with smoking being recognized as its most important causative factor. The most effective available treatment for COPD is smoking cessation. There is mounting evidence that the rate of progression of COPD can be reduced when patients at risk of developing the disease stop smoking, while lifelong smokers have a 50% probability of developing COPD during their lifetime. More significantly, there is also evidence that the risk of developing COPD falls by about half with smoking cessation. Several pharmacological interventions now exist to aid smokers in cessation; these include nicotine replacement therapy, bupropion, and varenicline. All pharmacotherapies for smoking cessation are more efficacious than placebo, with odds ratios of about 2. Pharmacologic therapy should be combined with nonpharmacologic (behavioral) therapy. Unfortunately, despite the documented efficacy of these agents, the absolute number of patients who are abstinent from smoking at 12 months of follow-up is low.http://www.mdpi.com/1660-4601/6/1/209/TobaccosmokingCOPDsmoking cessation
collection DOAJ
language English
format Article
sources DOAJ
author Rafael Laniado-Laborín
spellingShingle Rafael Laniado-Laborín
Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century
International Journal of Environmental Research and Public Health
Tobacco
smoking
COPD
smoking cessation
author_facet Rafael Laniado-Laborín
author_sort Rafael Laniado-Laborín
title Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century
title_short Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century
title_full Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century
title_fullStr Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century
title_full_unstemmed Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century
title_sort smoking and chronic obstructive pulmonary disease (copd). parallel epidemics of the 21st century
publisher MDPI AG
series International Journal of Environmental Research and Public Health
issn 1660-4601
publishDate 2009-01-01
description One hundred million deaths were caused by tobacco in the 20th century, and it is estimated that there will be up to one billion deaths attributed to tobacco use in the 21st century. Chronic obstructive pulmonary disease (COPD) is rapidly becoming a global public health crisis with smoking being recognized as its most important causative factor. The most effective available treatment for COPD is smoking cessation. There is mounting evidence that the rate of progression of COPD can be reduced when patients at risk of developing the disease stop smoking, while lifelong smokers have a 50% probability of developing COPD during their lifetime. More significantly, there is also evidence that the risk of developing COPD falls by about half with smoking cessation. Several pharmacological interventions now exist to aid smokers in cessation; these include nicotine replacement therapy, bupropion, and varenicline. All pharmacotherapies for smoking cessation are more efficacious than placebo, with odds ratios of about 2. Pharmacologic therapy should be combined with nonpharmacologic (behavioral) therapy. Unfortunately, despite the documented efficacy of these agents, the absolute number of patients who are abstinent from smoking at 12 months of follow-up is low.
topic Tobacco
smoking
COPD
smoking cessation
url http://www.mdpi.com/1660-4601/6/1/209/
work_keys_str_mv AT rafaellaniadolaboraƒan smokingandchronicobstructivepulmonarydiseasecopdparallelepidemicsofthe21stcentury
_version_ 1725405861539479552